{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:03:50Z","timestamp":1794330230718,"version":"4.9.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:p>\n                    Minimal change disease (MCD) has a high recurrence rate, with refractory MCD frequently requiring long-term corticosteroid therapy or combination regimens with other immunosuppressive agents. Rituximab (RTX) has been confirmed to be an effective treatment for refractory MCD. However, its role in remission maintenance remains uncertain. This study aimed to assess RTX dosing strategies, infusion intervals, and relapse predictors during the remission maintenance phase of refractory MCD. We conducted a retrospective analysis of 14 patients with refractory MCD who had achieved complete remission with corticosteroids or conventional immunosuppressants and subsequently received RTX during the maintenance phase. The mean follow-up period was 31.1\u2005\u00b1\u20059.6 months. RTX was administered intravenously at a dose of 375\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    body surface area or 1000\u2009mg every infusion. Based on their laboratory results, RTX therapy was administered in the patients intermittently. Patients who experienced recurrence were withdrawn from the study for further observation and management. Patients were treated with RTX at 375\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    body surface area or 1000\u2009mg with each infusion in the remission maintenance phase. The mean intervals from the first to second and from the second to third infusions were 7.9\u2005\u00b1\u20052.1 months and 11.8\u2005\u00b1\u20052.8 months, respectively. Eight patients remained in remission and 6 patients experienced a relapse. Steroids or immunosuppressants were discontinued in 12 patients, while a dose reduction was achieved in 2 others. The relapse frequency significantly decreased from 1.87 (0.43\u20132.69) to 0 (0.00\u20131.33;\n                    <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                    .05). Recurrence was negatively associated with additional annual RTX therapy (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .05). Serious side effects were not found. RTX is associated with reduced relapse frequency and earlier discontinuation of corticosteroids and immunosuppressants in refractory MCD patients during remission maintenance. Additional annual RTX administration represents an effective strategy for decreasing disease recurrence. Our findings suggest potential benefit of early administration. While findings are promising, larger controlled studies are necessary to establish optimal dosing intervals and long-term efficacy.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046798","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T21:00:08Z","timestamp":1766782808000},"page":"e46798","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase"],"prefix":"10.1097","volume":"104","author":[{"given":"Li","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjie","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhi","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8771-4386","authenticated-orcid":false,"given":"Shaomei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251226","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases.","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"R2-20251226","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes.","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R3-20251226","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/ndt\/gft312","article-title":"Rituximab for minimal change disease in adults: long-term follow-up.","volume":"29","author":"Bruchfeld","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R4-20251226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"BMC Nephrol"},{"key":"R5-20251226","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","article-title":"Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.","volume":"14","author":"Xue","year":"2021","journal-title":"Clin Kidney J"},{"key":"R6-20251226","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ekir.2023.02.1070","article-title":"Rituximab as initial therapy in adult patients with minimal change disease.","volume":"8","author":"Guan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"R7-20251226","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000535010","article-title":"Efficacy of rituximab for minimal change disease and focal segmental glomerulosclerosis with frequently relapsing or steroid-dependent nephrotic syndrome in adults: a chinese multicenter retrospective study.","volume":"55","author":"Lan","year":"2024","journal-title":"Am J Nephrol"},{"key":"R8-20251226","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s10157-020-01943-3","article-title":"Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.","volume":"24","author":"Taguchi","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"R9-20251226","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12882-023-03092-7","article-title":"Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.","volume":"24","author":"Zhang","year":"2023","journal-title":"BMC Nephrol"},{"key":"R10-20251226","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1007\/s00467-006-0228-x","article-title":"Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.","volume":"21","author":"Gilbert","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R11-20251226","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","article-title":"Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.","volume":"107","author":"Perosa","year":"2006","journal-title":"Blood"},{"key":"R12-20251226","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"R13-20251226","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.kint.2025.02.028","article-title":"Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis.","volume":"108","author":"Shu","year":"2025","journal-title":"Kidney Int"},{"key":"R14-20251226","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.kint.2024.09.006","article-title":"Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants.","volume":"106","author":"Raglianti","year":"2024","journal-title":"Kidney Int"},{"key":"R15-20251226","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R16-20251226","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","article-title":"Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.","volume":"28","author":"Takei","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R17-20251226","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"key":"R18-20251226","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","article-title":"Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.","volume":"23","author":"Guigonis","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R19-20251226","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R20-20251226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatr Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:23:45Z","timestamp":1785857025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":20,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046798","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2025-08-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}